For semaglutide, this process must be done with care to ensure the medication works as intended
Lillys Easy-to Use Once-Weekly GLP-1 Agonist Trulicity Approved in Europe Twitter Summary: Lillys Trulicity, a once-weekly GLP-1 agonist available in US, has now been approved in Europe On November 25, Eli Lillys Trulicity (dulaglutide) was approved in Europe for type 2 diabetes
doi:10.1093/ajcn/87.5.1446 Pagana, Kathleen Deska, et al
Each needle puncture introduces a pathway for bacteria
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving semaglutide than placebo (placebo 15.3%, semaglutide 0.5 mg 32.7%, semaglutide 1 mg 36.4%)